<DOC>
	<DOCNO>NCT02866461</DOCNO>
	<brief_summary>This study design study brain mechanism associate symptom severity Fibromyalgia . This accomplish relate result PET scan self-reported objective measure disease severity .</brief_summary>
	<brief_title>Endogenous Opioid Systems Symptom Change Fibromyalgia</brief_title>
	<detailed_description>The purpose study examine µ-opioid receptor ( µOR ) -mediated neurotransmission patient diagnose persistent pain , fibromyalgia ( FM ) , relationship pain affect measure . µOR activation expect take place follow brain region : rostral dorsal anterior cingulate ( rACC , dACC ) , orbitofrontal cortex ( OFC ) , thalamus ( THA ) , nucleus accumbens ( NAC ) , amygdala ( AMY ) , periaqueductal gray ( PAG ) . Greater regional activation expect associated improvement clinical pain rating affective state . The endogenous opioid system µ-opioid receptor ( µORs ) play central role regulation pain , pathophysiology chronic pain syndrome , mood emotion ; system dysregulated persistent pain syndrome . A substantial body literature address mechanism develop laboratory , include recent data cognitive molecular mechanism associate reduction pain , well trait personality genetic predictor emotional effect context pain . Eighty individual diagnose FM fit inclusion exclusion criterion enrol 14-week protocol . An initial visit inform consent procedure baseline characterization schedule , well visit positron emission tomography ( PET ) magnetic resonance imaging ( MRI ) procedure . Subjects return test 6 14 week . Volunteers undergo image structural functional MRI PET [ 11C ] carfentanil determine baseline µOR non-displaceable binding potential ( BPND ) change BPND measure coincide symptom severity time scan .</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Endorphins</mesh_term>
	<criteria>Have meet American College Rheumatology ( ACR ) criteria fibromyalgia least 1 year ; Willing limit introduction new treatment study ; Use sleep aid twice per week 1855 year age right hand capable provide write informed consent concurrent untreated medical illness , autoimmune , inflammatory disease ; Routine daily use narcotic analgesic history substance abuse ; Concurrent participation therapeutic trial ; Pregnancy/ nursing ; Ongoing psychiatric illness ; Contraindications PET MRI method ; Impairments would prevent completion study protocol ; Use sleep aid frequency twice per week ; Allergy fentanyl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>